TNFRSF13C and systemic lupus erythematosus: Therapeutic interventions aimed at BAFF/BAFFR and APRIL are primarily employed in the clinical context to address autoimmune diseases such as multiple sclerosis (MS), rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE), as well as graft-vs.-host disease (114–116).